Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2024-08-13 00:00:00 ET · period of report 2024-08-09 · accession 0001415889-24-021154 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-13 | 2024-08-09 | ACRS | Walker Neal | INTERIM Pres AND CEO, Dir | M - OptEx | $0.72 | +43.5K | 1.36M | +3% | +$31.4K |
| D | 2024-08-13 | 2024-08-09 | ACRS | Walker Neal | INTERIM Pres AND CEO, Dir | M - OptEx | $0.00 | -43.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-09 | M | A | 43,548 | $0.72 | 1,356,153 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2024-08-09 | M | D | 43,548 | $0.00 | 0 | D | $0.72 · — to 2024-08-12 | 43,548 Common Stock | (F1) Fully vested and exercisable. |